Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Clinical Activity of Single Agent Pertuzumab (rhuMab 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer (OC): Potential Predictive Relationship with Tumor HER2 Activation Status.

Clinical Activity of Single Agent Pertuzumab (rhuMab 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer (OC): Potential Predictive Relationship with Tumor HER2 Activation Status. . SGO. 2006; 20(abstract 20).


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.